NewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)
NewAmsterdam Pharma (NASDAQ:NAMS) First Half 2023 Results
Key Financial Results
Revenue: €9.56m (down 90% from 1H 2022).
Net loss: €75.1m (down by 238% from €54.5m profit in 1H 2022).
€0.92 loss per share (down from €1.50 profit in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NewAmsterdam Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for NewAmsterdam Pharma that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
